Provided by Tiger Trade Technology Pte. Ltd.

MBX Biosciences

31.79
-0.0900-0.28%
Volume:180.39K
Turnover:5.74M
Market Cap:1.51B
PE:-14.54
High:32.17
Open:31.80
Low:31.06
Close:31.88
52wk High:45.85
52wk Low:9.43
Shares:47.51M
Float Shares:25.72M
Volume Ratio:0.66
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1861
EPS(LYR):-2.3824
ROE:-25.73%
ROA:-17.68%
PB:3.45
PE(LYR):-13.34

Loading ...

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

GlobeNewswire
·
May 26

LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)

TIPRANKS
·
May 16

Mbx Biosciences Inc : Stifel Raises Target Price to $56 From $50

THOMSON REUTERS
·
May 12

MBX Biosciences price target raised to $86 from $76 at Citizens

TIPRANKS
·
May 12

MBX Biosciences CMO Salomon Azoulay disposes of USD 2.68 million common shares

Reuters
·
May 12

BUZZ-U.S. STOCKS ON THE MOVE-Barrick Mining, Lumentum, Tesla

Reuters
·
May 12

BUZZ-MBX rises on obesity drug data showing monthly dosing potential

Reuters
·
May 11

MBX Biosciences Is Maintained at Buy by Truist Securities

Dow Jones
·
May 11

Stock Track | MBX Biosciences Soars 5.92% Intraday on Positive Obesity Drug Data and Analyst Upgrades

Stock Track
·
May 11

MBX Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Truist Raises Price Target on MBX Biosciences to $70 From $50, Keeps Buy Rating

MT Newswires Live
·
May 11

MBX Biosciences, Inc. (MBX) Gets a Buy from Guggenheim

TIPRANKS
·
May 11

MBX Biosciences Highlights Positive Phase 1 Obesity Data

TIPRANKS
·
May 11

MBX Biosciences reports 7% mean weight loss at 8 weeks in MBX 4291 Phase 1 trial

Reuters
·
May 11

Mbx Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for Mbx 4291 Supporting Potential for Once-Monthly Dosing

THOMSON REUTERS
·
May 11

Mbx Biosciences Inc - Ind-Enabling Studies for Mbx 5765 Expected to Begin in Q2 2026

THOMSON REUTERS
·
May 11

Mbx Biosciences Inc - 4291 12-Week Phase 1 Mad Part C Data on Track for Q4 2026

THOMSON REUTERS
·
May 11

Mbx Biosciences Inc - 4291 Generally Well Tolerated With Minimal Gi Events at 8 Weeks

THOMSON REUTERS
·
May 11

Mbx Biosciences Inc - 4291 Phase 1 Data Show Mean Weight Loss of 7% at 8 Weeks

THOMSON REUTERS
·
May 11

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

GlobeNewswire
·
May 11